Selections of Antithrombotic Agents During Acute Stage

  • Tomohisa NezuEmail author
  • Naohisa Hosomi
  • Masayasu Matsumoto
Part of the Stroke Revisited book series (STROREV)


There are two major classes of antithrombotic agents that can be used in acute stroke settings, namely, antiplatelet agents and anticoagulant agents. Aspirin is recommended to use as soon as possible (within 48 h after stroke onset) for acute ischemic stroke patients. Recently, short-term dual antiplatelet therapy (aspirin plus clopidogrel) has been indicated to be safe and superior to aspirin in acute ischemic stroke patients in China. However, the dual antiplatelet therapy with aspirin and clopidogrel is not recommended as stroke prevention for the long term. Early anticoagulation occasionally might be used for certain stroke patients, although it is not recommended in general. Oral anticoagulation is recommended for secondary stroke prevention in patients with cardioembolic stroke. However, the initial timing of anticoagulation in acute stroke setting in cardioembolic stroke patients remains unclear. Further prospective studies to evaluate the safety, efficacy, optimal term, or optimal selections of antithrombotic agents will be needed for the acute ischemic stroke patients, considering the etiology of stroke. Physicians should consider the etiology of stroke (at least, cardioembolic stroke or non-cardioembolic stroke) to select the antithrombotic agents.


  1. 1.
    Lansberg MG, O’Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e601S–36S.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang Q, Wang C, Zheng M, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis. 2015;39:13–22.CrossRefPubMedGoogle Scholar
  4. 4.
    The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569–81.Google Scholar
  5. 5.
    CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349:1641–9.Google Scholar
  6. 6.
    Sandercock PA, Counsell C, Tseng MC, et al. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;(3):CD000029.Google Scholar
  7. 7.
    Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6:961–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:489–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111:2233–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang Y, Zhao X, Liu L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Hong KS, Lee SH, Kim EG, et al. Recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone. Stroke. 2016;47:2323–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316:70–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol. 2010;56:1542–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–51.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Dengler R, Diener HC, Schwartz A, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:159–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959–68.CrossRefPubMedGoogle Scholar
  21. 21.
    Shimizu H, Tominaga T, Ogawa A, et al. Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. J Stroke Cerebrovasc Dis. 2013;22:449–56.CrossRefPubMedGoogle Scholar
  22. 22.
    Teruo K, Tucker A, Sugimura T, et al. Ultra-early combination antiplatelet therapy with cilostazol for the prevention of branch atheromatous disease: a multicenter prospective study. Cerebrovasc Dis Extra. 2016;6:84–95.CrossRefGoogle Scholar
  23. 23.
    Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2002;(4):CD003242.Google Scholar
  25. 25.
    Kern R, Nagayama M, Toyoda K, et al. Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis. 2013;35:402–18.CrossRefPubMedGoogle Scholar
  26. 26.
    Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMedGoogle Scholar
  31. 31.
    Arihiro S, Todo K, Koga M, et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke. 2016;11:565–74.CrossRefPubMedGoogle Scholar
  32. 32.
    Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA. 1998;279:1265–72.Google Scholar
  33. 33.
    Wong KS, Chen C, Ng PW, et al. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol. 2007;6:407–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Wada T, Yasunaga H, Horiguchi H, et al. Outcomes of argatroban treatment in patients with atherothrombotic stroke: observational nationwide study in Japan. Stroke. 2016;47:471–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Hosomi N, Naya T, Kohno M, et al. Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke. J Neurol. 2007;254:605–12.CrossRefPubMedGoogle Scholar
  36. 36.
    Markus HS, Hayter E, Levi C, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14:361–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2017

Authors and Affiliations

  • Tomohisa Nezu
    • 1
    Email author
  • Naohisa Hosomi
    • 1
  • Masayasu Matsumoto
    • 1
    • 2
  1. 1.Department of Clinical Neuroscience and TherapeuticsHiroshima University Graduate School of Biomedical & Health SciencesHiroshimaJapan
  2. 2.Japan Community Healthcare Organization (JCHO), Hoshigaoka Medical CenterHirakataJapan

Personalised recommendations